Compare Stocks: RPTX, CCCC, OCGN, and PRLD

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$3.76 +0.5%	$3.92	$1.69 ▼ $5.17	$462.59M	2.94	2.68 million shs	2.36 million shs
OCGN Ocugen	$1.36 +0.4%	$1.37	$1.01 ▼ $2.73	$459.49M	2.2	6.94 million shs	3.55 million shs
PRLD Prelude Therapeutics	$5.46 +4.0%	$5.04	$0.98 ▼ $6.83	$435.71M	0.97	427,919 shs	400,284 shs
RPTX Repare Therapeutics	$2.65 +0.8%	$2.62	$1.24 ▼ $2.66	$114.24M	0.97	516,093 shs	1.22 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	-1.32%	-8.78%	+3.60%	-2.86%	+46.09%
OCGN Ocugen	+2.27%	-1.46%	+3.05%	+5.47%	+28.57%
PRLD Prelude Therapeutics	-3.31%	-17.19%	+16.15%	+37.80%	+330.33%
RPTX Repare Therapeutics	0.00%	0.00%	0.00%	0.00%	+54.07%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CCCC C4 Therapeutics	$3.76 +0.5%	$3.92	$1.69 ▼ $5.17	$462.59M	2.94	2.68 million shs	2.36 million shs
OCGN Ocugen	$1.36 +0.4%	$1.37	$1.01 ▼ $2.73	$459.49M	2.2	6.94 million shs	3.55 million shs
PRLD Prelude Therapeutics	$5.46 +4.0%	$5.04	$0.98 ▼ $6.83	$435.71M	0.97	427,919 shs	400,284 shs
RPTX Repare Therapeutics	$2.65 +0.8%	$2.62	$1.24 ▼ $2.66	$114.24M	0.97	516,093 shs	1.22 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CCCC C4 Therapeutics	-1.32%	-8.78%	+3.60%	-2.86%	+46.09%
OCGN Ocugen	+2.27%	-1.46%	+3.05%	+5.47%	+28.57%
PRLD Prelude Therapeutics	-3.31%	-17.19%	+16.15%	+37.80%	+330.33%
RPTX Repare Therapeutics	0.00%	0.00%	0.00%	0.00%	+54.07%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CCCC C4 Therapeutics	2.60	Moderate Buy	$7.67	103.90% Upside
OCGN Ocugen	2.60	Moderate Buy	$9.50	601.11% Upside
PRLD Prelude Therapeutics	2.40	Hold	$7.67	40.42% Upside
RPTX Repare Therapeutics	2.00	Hold	$3.00	13.21% Upside

Current Analyst Ratings Breakdown

Latest RPTX, CCCC, OCGN, and PRLD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2026	OCGN Ocugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/17/2026	CCCC C4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/23/2026	OCGN Ocugen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CCCC C4 Therapeutics	$35.95M	12.87	N/A	N/A	$2.01 per share	1.87
OCGN Ocugen	$4.41M	104.19	N/A	N/A	($0.05) per share	-27.10
PRLD Prelude Therapeutics	$12.14M	35.89	N/A	N/A	$1.68 per share	3.25
RPTX Repare Therapeutics	$11.87M	9.62	N/A	N/A	$3.56 per share	0.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CCCC C4 Therapeutics	-$104.99M	-$1.00	N/A	N/A	N/A	-289.44%	-45.45%	-30.90%	11/5/2026 (Estimated)
OCGN Ocugen	-$67.85M	-$0.26	N/A	N/A	N/A	N/A	-127,987.80%	-115.95%	11/4/2026 (Estimated)
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)
RPTX Repare Therapeutics	-$84.69M	-$1.69	N/A	N/A	N/A	N/A	-60.15%	-52.24%	N/A

Latest RPTX, CCCC, OCGN, and PRLD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/6/2026	Q2 2026	OCGN Ocugen	-$0.0533	-$0.07	-$0.0167	-$0.07	$0.89 million	$1.49 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
RPTX Repare Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CCCC C4 Therapeutics	N/A	5.45	5.45
OCGN Ocugen	4.17	0.80	0.80
PRLD Prelude Therapeutics	N/A	4.07	4.07
RPTX Repare Therapeutics	N/A	10.71	10.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CCCC C4 Therapeutics	78.81%
OCGN Ocugen	10.27%
PRLD Prelude Therapeutics	79.72%
RPTX Repare Therapeutics	85.09%

Insider Ownership

Company	Insider Ownership
CCCC C4 Therapeutics	5.60%
OCGN Ocugen	3.95%
PRLD Prelude Therapeutics	49.20%
RPTX Repare Therapeutics	11.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CCCC C4 Therapeutics	150	123.03 million	116.14 million	Optionable
OCGN Ocugen	80	339.11 million	325.72 million	Optionable
PRLD Prelude Therapeutics	120	79.80 million	40.54 million	Optionable
RPTX Repare Therapeutics	180	43.11 million	38.15 million	Optionable

RPTX, CCCC, OCGN, and PRLD Headlines

Recent News About These Companies

Repare Therapeutics Sells RP-3467 Cancer Program Assets to Gilead for Up to $30 Million

July 27, 2026 | theglobeandmail.com

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

January 16, 2026 | financialpost.comF

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

January 16, 2026 | businesswire.com

Repare Therapeutics announces Gilead to acquire RP-3467 for up to $30M

December 25, 2025 | msn.com

Why Repare Therapeutics Inc.’s (RPTX) Stock Is Up 19.82%

December 25, 2025 | aaii.comA

RPTX stock soars pre-market after Gilead agrees to acquire investigational cancer drug

December 24, 2025 | msn.com

Repare Therapeutics stock soars after Gilead Sciences deal for cancer drug

December 24, 2025 | ca.investing.com

Gilead to buy Repare Thera’s cancer candidate for up to $30M

December 24, 2025 | msn.com

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

December 24, 2025 | businesswire.com

Halper Sadeh LLC Encourages RPTX, THS, RMBI Shareholders to Contact the Firm to Discuss Their Rights

November 27, 2025 | caledonianrecord.comC

Repare shareholders vote in favor of Xeno bid

November 22, 2025 | thepharmaletter.comT

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

November 20, 2025 | financialpost.comF

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

November 20, 2025 | businesswire.com

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights

November 18, 2025 | globenewswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)

November 17, 2025 | globenewswire.com

Repare Therapeutics downgraded to Hold from Buy at TD Cowen

November 17, 2025 | msn.com

Repare Therapeutics stock soars after acquisition deal with XenoTherapeutics

November 14, 2025 | za.investing.com

XenoTherapeutics to acquire Repare Therapeutics for $1.82 p/s plus one CVR

November 14, 2025 | msn.com

Repare Therapeutics enters into definitive agreement to be acquired by xenotherapeutics

November 14, 2025 | msn.com

RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders

November 14, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, CCCC, OCGN, and PRLD Company Descriptions

C4 Therapeutics NASDAQ:CCCC

$3.76 +0.02 (+0.53%)

As of 04:00 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Ocugen NASDAQ:OCGN

$1.36 +0.01 (+0.37%)

As of 04:00 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Prelude Therapeutics NASDAQ:PRLD

$5.46 +0.21 (+4.00%)

As of 04:00 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Repare Therapeutics NASDAQ:RPTX

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RPTX, CCCC, OCGN, and PRLD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RPTX, CCCC, OCGN, and PRLD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPTX, CCCC, OCGN, and PRLD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, CCCC, OCGN, and PRLD Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Ocugen NASDAQ:OCGN

Prelude Therapeutics NASDAQ:PRLD

Repare Therapeutics NASDAQ:RPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RPTX, CCCC, OCGN, and PRLD Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RPTX, CCCC, OCGN, and PRLD Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RPTX, CCCC, OCGN, and PRLD Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

RPTX, CCCC, OCGN, and PRLD Company Descriptions

C4 Therapeutics NASDAQ:CCCC

Ocugen NASDAQ:OCGN

Prelude Therapeutics NASDAQ:PRLD

Repare Therapeutics NASDAQ:RPTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools